Imaging: Mass spectrometry in HNSCCa peek at response prediction?

Nature Reviews Clinical Oncology

Volumn 7, Issue 4, 2010, Pages 193-195

  Ang, Mei Kim ^a   Hayes, D Neil ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR;

COLORECTAL CANCER; DRUG RESPONSE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LUNG NON SMALL CELL CANCER; MASS SPECTROMETRY; OVERALL SURVIVAL; PRIORITY JOURNAL; SHORT SURVEY; SURVIVAL PREDICTION;

ALGORITHMS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; MASS SPECTROMETRY; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK FACTORS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 77950510220     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2010.35     Document Type: Short Survey

References (10)

1. Taguchi, F. et al. Mass spectrometry to classify non-small cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross institutional study. J. Natl Cancer Inst. 99, 838-846 (2007).
2. Carbone, D. P. et al. veristratR classifier for survival and time to progression in non-small cell lung cancer (nsCLC) patients treated with erlotinib and bevacizumab. Lung Cancer doi:10.1016/j.lungcan.2009.11.019
3. Amann J. M. et al. Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in eastern Cooperative Oncology Group 3503. J. Thorac. Oncol. 5, 169-178 (2010).
4. salmon, s. et al. Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen. J. Thorac. Oncol. 4, 689-696 (2009).
5. Chung, C. H. et al. Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients. Cancer Epidemiol. Biomarkers Prev. 19, 358-365 (2010).
6. Ocak, s., Chaurand, P. & Massion, P. P. Mass spectrometry-based profiling of lung cancer. Proc. Am. Thorac. Soc. 6, 159-170 (2009).
7. Diamandis, e. P. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J. Natl Cancer Inst. 96, 353-356 (2004).
8. Bernier, J., Bentzen, s. M. & vermorken, J. B. Molecular therapy in head and neck oncology. Nat. Rev. Clin. Oncol. 6, 266-277 (2009).
9. Cooper, J. B. & Cohen, e. e. Mechanisms of resistance to eGFR inhibitors in head and neck cancer. Head Neck 31, 1086-1094 (2009).
10. Govindan, R. inTeResTing biomarker to select iDeAL patients for epidermal growth factor receptor tyrosine kinase inhibitors: Yes, for eGFR mutation analysis, Others, i PAss. J. Clin. Oncol. 28, 713-715 (2010).